Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.
Epstein-Barr virus (EBV) infection and reactivation is an increasing complication in immune deficient patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT). Therapy with anti-thymocyte globulin (ATG) is associated with higher incidence of EBV-related disease in HSCT patients, but this risk is not documented in patients receiving ATG for severe aplastic anemia (SAA). We describe the case of a patient who developed an EBV infection, with the clinical features of an infectious mononucleosis, after immune suppression with cyclosporine and two courses of ATG for SAA.
Calistri
Elisabetta
E
Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy.
Tiribelli
Mario
M
Battista
Marta
M
Michelutti
Angela
A
Corbellino
Mario
M
Viale
Pierluigi
P
Fanin
Renato
R
Damiani
Daniela
D
D000328:Adult; D000741:Anemia, Aplastic / Q000188:drug therapy* / Q000276:immunology; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D020031:Epstein-Barr Virus Infections / Q000209:etiology* / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009894:Opportunistic Infections / Q000209:etiology* / Q000276:immunology
D000961:Antilymphocyte Serum; D004279:DNA, Viral; D007166:Immunosuppressive Agents